Ditropan XL ® is also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product. Dosage may then be increased by 2.5mg daily at 2 to 3 day intervals, as follows:- 2.5mg eight hourly, 2.5mg six hourly, 5mg six hourly. When suggestions are available use up and down arrows to review and ENTER to select. Should it be advisable to reduce the dosage of levodopa because of adverse reactions, the daily dosage of Bromocriptine, if increased, should be accomplished gradually in small (2.5 mg) increments.The safety of Bromocriptine has not been demonstrated in dosages exceeding 100 mg/day.Bromocriptine mesylate tablets are available in bottles containing 30 and 100 tablets of 2.5 mg - each bottle contains a desiccant.Round, off-white, bevelled-edge scored tablets, each containing 2.5 mg Bromocriptine (as the mesylate). If necessary, the dosage may be increased every 14 to 28 days by 2.5 mg/day with meals. The highest doses tested in mice and rats were approximately 2.5 and 4.4 times, respectively, the maximum human dose administered in controlled clinical trials (100 mg/day) based on body surface area. Name /bks_53161_deglins_md_disk/oxybutynin 03/14/2014 07:51AM Plate # 0-Composite pg 2 # 2 2015 F.A. No data are available for Bromocriptine use in pediatric patients under the age of 8 years. Does Ditropan XL Interact with other Medications? Bromocriptine medication should be withdrawn if fibrotic changes in the retroperitoneum are diagnosed or suspected.There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including Bromocriptine, that increase central dopaminergic tone. The dopaminergic neurons in the tuberoinfundibular process modulate the secretion of prolactin from the anterior pituitary by secreting a prolactin inhibitory factor (thought to be dopamine); in the corpus striatum the dopaminergic neurons are involved in the control of motor function. Concomitant use of bromocriptine with vasoconstrictors such as sympathomimetics or ergot alkaloids including ergometrine or methylergometrine during the puerperium is not recommended. Bromolysergic acid and bromoisolysergic acid accounted for half of the radioactivity in urine.The effect of renal function on the pharmacokinetics of Bromocriptine has not been evaluated.Since parent drug and metabolites are almost completely excreted via metabolism, and only 6% eliminated via the kidney, renal impairment may not have a significant impact on the PK of Bromocriptine and its metabolites (see The effect of liver impairment on the PK of Bromocriptine and its metabolites has not been evaluated. Patients with a history of evidence of peptic ulceration should be closely monitored when receiving the treatment.Since, especially during the first few days of treatment, hypotensive reactions may occasionally occur and result in reduced alertness, particular care should be exercised when driving a vehicle or operating machinery.Among patients on BROMOCRIPTINE, particularly on long-term and high-dose treatment, pleural and pericardial effusions, as well as pleural and pulmonary fibrosis and constrictive pericarditis have occasionally been reported. If hypertension, severe, progressive, or unremitting headache (with or without visual disturbances), or evidence of CNS toxicity develop, the administration of Bromocriptine should be discontinued and the patient should be evaluated promptly.Particular caution is required in patients who have recently been treated or are on concomitant therapy with drugs that can alter blood pressure, e.g., vasoconstrictors such as sympathomimetics or ergot alkaloids, including ergometrine or methylergometrine and their concomitant use in the puerperium is not recommended.To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-406-7984 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.The most commonly reported signs and symptoms associated with acute Bromocriptine mesylate overdose are: nausea, vomiting, constipation, diaphoresis, dizziness, pallor, severe hypotension, malaise, confusion, lethargy, drowsiness, delusions, hallucinations, and repetitive yawning. The major binding protein is alpha-1 acid glycoprotein.Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4 found mostly in the liver and gut wall. In these cases the visual field defect may improve on reduction of bromocriptine dosage while there is some elevation of prolactin and some tumour re-expansion.